- Home
- REFR vs ANVS Comparison
REFR vs ANVS Comparison
Compare REFR & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFR
- ANVS
- Stock Information
- Founded
- REFR 1965
- ANVS 2008
- Country
- REFR United States
- ANVS United States
- Employees
- REFR N/A
- ANVS N/A
- Industry
- REFR Multi-Sector Companies
- ANVS Biotechnology: Pharmaceutical Preparations
- Sector
- REFR Miscellaneous
- ANVS Health Care
- Exchange
- REFR Nasdaq
- ANVS Nasdaq
- Market Cap
- REFR 49.5M
- ANVS 55.5M
- IPO Year
- REFR N/A
- ANVS 2020
- Fundamental
- Price
- REFR $1.25
- ANVS $2.48
- Analyst Decision
- REFR
- ANVS Strong Buy
- Analyst Count
- REFR 0
- ANVS 4
- Target Price
- REFR N/A
- ANVS $17.33
- AVG Volume (30 Days)
- REFR 25.8K
- ANVS 210.1K
- Earning Date
- REFR 11-06-2025
- ANVS 11-07-2025
- Dividend Yield
- REFR N/A
- ANVS N/A
- EPS Growth
- REFR N/A
- ANVS N/A
- EPS
- REFR N/A
- ANVS N/A
- Revenue
- REFR $1,222,239.00
- ANVS N/A
- Revenue This Year
- REFR N/A
- ANVS N/A
- Revenue Next Year
- REFR N/A
- ANVS N/A
- P/E Ratio
- REFR N/A
- ANVS N/A
- Revenue Growth
- REFR N/A
- ANVS N/A
- 52 Week Low
- REFR $0.93
- ANVS $1.11
- 52 Week High
- REFR $2.35
- ANVS $10.54
- Technical
- Relative Strength Index (RSI)
- REFR 32.31
- ANVS 52.16
- Support Level
- REFR $1.24
- ANVS $2.26
- Resistance Level
- REFR $1.33
- ANVS $2.51
- Average True Range (ATR)
- REFR 0.06
- ANVS 0.12
- MACD
- REFR -0.00
- ANVS 0.02
- Stochastic Oscillator
- REFR 12.00
- ANVS 87.10
About REFR Research Frontiers Incorporated
Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light. The company develops and licenses its patented suspended particle device light-control technology to other companies that manufacture and market the SPD-Smart chemical emulsion, the light-control film made from the chemical emulsion, the light-control panels made by laminating the film, electronics to power end-products incorporating the film, or lamination services for, and the end-products. The company's revenue source comes from the licensing of technology.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.